Fampridina na Esclerose Múltipla – para além da marcha
DOI:
https://doi.org/10.25759/spmfr.243Keywords:
Esclerose Múltipla, Fampridina, Marcha, EquilíbrioAbstract
Objetivos: É objetivo do estudo a avaliação do impacto da Fampridina na marcha, equilíbrio, nível funcional e perceção da capacidade de marcha em doentes com Esclerose Múltipla.
Material e Métodos: Estudo prospetivo, aberto, não controlado e não randomizado, em doentes com Esclerose Múltipla e EDSS entre 4,0-7,0 sob tratamento com Fampridina. Foram usados para a avaliação do impacto da Fampridina: Multiple Sclerosis Walking Scale 12 (MSWS-12), Timed 25-Foot Walk (T25FW), Timed Up and Go (TUG) e Escala de Equilíbrio de Berg (EEB). A análise estatística foi efetuada com um nível de significância estatística de p<0,05.
Resultados: Um total de 15 doentes (88,24%) foram considerados respondedores. O aumento do equilíbrio, velocidade da marcha e na perceção da capacidade para a marcha foram estatisticamente significativos com melhoria média de 19,08% (± 31,11) no T25FW (p=0,022), 19,20% (±26,13) na EEB (p=0,012), 35,97% (±34,93) no TUG (p=0,022) e 12,99% (±12,90) na MSWS-12 (p=0,016). Há uma correlação forte e estatisticamente significativa entre TUG e T25FW (r= 0,668, p= 0,017).
Conclusões: Os resultados preliminares mostram a potencialidade da Fampridina no aumento da velocidade da marcha, equilíbrio e perceção da capacidade da marcha em doentes com Esclerose Múltipla. São necessários estudos para caracterizar os preditores de eficácia de resposta e avaliação do potencial do fármaco noutros níveis funcionais.
Downloads
References
Keune PM, Cocks AJ, Young WR, Burschka JM, Hansen S, Hofstadt-van Oy U, et al. Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine). BMC Neurol. 2015 Sep 24;15:17
Blight AR, Henney HR, Cohen R. Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis. Ann N Y Acad Sci. 2014 Nov; 1329:33-44
Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology. 2007 May, 68 (Suppl. 3): S22–S31
Rudick RA, Cutter G, Reingold S. The Multiple Sclerosis Functional Composite; a new clinical outcome measure for multiple sclerosis clinical trials. Mult Scler. 2002 Oct; 8: 359–65.
Dunn J. Impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis. Expert Rev. Pharmacoecon. Outcomes Res. 2010 Aug; 10(4): 433–40.
Pike J, Jones E, Rajagopalan K, Piercy J, Anderson P. Social and economic burden of walking and mobility problems in multiple sclerosis. BMC Neurol. 2012 Sep 18; 12:94.
Preiningerova JL, Baumhackl U, Csepany T, Czaplinski A, Deisenhammer F, Derfuss T, et al. Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS). CNS Neurosci. Ther. 2013 May; 19(5): 302–6.
Dunn J, Blight A. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Curr. Med. Res. Opin. 2011 Jul; 27(7): 1415–23.
Krishnan AV, Kiernan MC. Sustained-release fampridine and the role of ion channel dysfunction in multiple sclerosis. Mult Scler. 2013 Apr; 19(4): 385–91.
Jensen HB, Ravnborg M, Dalgas U, Stenager E. 4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review. Ther Adv Neurol Disord. 2014 Mar; 7(2): 97–113.
Chwieduk CM, Keating GM. Dalfampridine extended release: in multiple sclerosis, CNS Drugs. 2010 Oct; 24(10): 883–91.
Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol. 2010 Oct; 68(4): 494-502
Goodman AD, Brown TR, Krupp TR, Schapiro RT, Schwid SR, Cohen, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009 Feb 28; 373(9665): 732-8.
Allart E, Benoit A, Blanchard-Dauphin A, Tiffreau V, Thevenon A, Zephir H, et al. Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life. J Neurol. 2015 Aug; 262(8): 1936-45
Pavsic K, Pelicon K, Ledinek AH, Sega S. Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients. Clin Neurol Neurosurg. 2015 Dec;139:35-40
Ruck T, Bittner S, Simon OJ, Göbel K, Wiendl H, Schilling M, et al., Long-term effects of dalfampridine in patients with multiple sclerosis, J. Neurol Sci. 2014 Feb 15; 337(1–2): 18–24.
Goodman AD, Bethoux F, Brown TR, Schapiro RT, Cohen R, Marinucci LN, et al. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: results of open-label extensions of two phase 3 clinical trials. Mult Scler. 2015 Sep; 21(10): 1322-31.
Rossini PM, Pasqualetti P, Pozzilli C, Grasso MG, Millefiorini E, Graceffa A, et al., Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine, Mult Scler. 2001 Dec; 7(6): 354–358.
Jensen HB, Ravnborg M, Mamoei S, Dalgas U, Stenager U. Changes in cognition, arm function and lower body function after slow-release fampridine treatment. Mult Scler. 2014 Dec; 20(14): 1872-8.
Hupperts R, Lycke J, Short C, Gasperini C, McNeill M, Medori R, et al. Prolonged-release fampridine and walking and balance in MS: randomized controlled MOBILE trial. Mult Scler. 2016 Feb;22(2):212-21.
Khan F, Turner-Stokes L, Ng L, Kilpatrick T. Multidisciplinary rehabilitation for adults with multiple sclerosis. Cochrane Database Syst Rev. 2007 Apr 18; (2): CD006036
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 Jul; 50(1): 121–7.
Published
How to Cite
Issue
Section
License
Copyright statement
Authors must also submit a copyright statement (as seen below) on article submission.
To the Editor-in-chief of the SPMFR Journal:
The below signed author(s) hereby state that the article
________________________________________ (ref. MFR_________) is
an original unpublished work and all facts stated are a product of the author(s) investigation. This article does not violate any copyright laws or privacy statements. The author(s) also hereby confirm that there is no conflict of interest's issues in this article.
By submitting this article the author(s) agree that after publication all copyrights belong to the SPMFR Journal.
Signed by all authors
Date:
Names (capital letters):
Signatures:
The SPMFR Journal’s contents are follow a Creative Commons licence. After publication the authors can hand out the articles as long as the SPMFR Journal is credited.
